奥精医疗科技股份有限公司 关于取消监事会、增加注册资本并修订 《公司章程》及制定、修订部分治理制度的 公告

Core Points - The company has decided to cancel its supervisory board and increase its registered capital, along with revising its articles of association and governance systems to comply with new regulations [1][3][4] Group 1: Cancellation of Supervisory Board - The company will no longer have a supervisory board or supervisors, with the audit committee of the board taking over the supervisory functions as per the Company Law [1][2] - The relevant rules regarding the supervisory board will be abolished, and corresponding amendments will be made to the articles of association [1][2] Group 2: Increase in Registered Capital - The company has completed the registration of shares for the second vesting period of its 2023 restricted stock incentive plan, resulting in an increase in share capital by RMB 1,457,000 and capital reserve by RMB 13,248,486.43 [3] - The total share capital will change from 135,551,584 shares to 137,008,584 shares, and the registered capital will increase from RMB 135,551,584 to RMB 137,008,584 [3] Group 3: Revision of Articles of Association - The company plans to amend its articles of association to enhance governance structure in line with the new regulations and its strategic development needs [4][5] - The definition of senior management will be adjusted by removing the "Chief Scientist" position, thus changing the definition of senior management to include only the General Manager, Deputy General Managers, Board Secretary, and Financial Officer [4][5] - Numerous amendments will be made to the articles of association, including the uniform change of "Shareholders' Meeting" to "Shareholders' Assembly" and the removal of all references to the supervisory board [5]